Mylan's Semglee Launch Marks US Multi-Source Competition To Lantus

Mylan N.V. is launching Semglee (insulin glargine) as a follow-on version of Sanofi's long-acting insulin Lantus at a list price that will be the lowest available, according to the company. The wholesale acquisition cost (WAC) of Semglee will be $147.98 for a package of five 3mL pens and $98.65 for a 10mL vial, a price which Mylan says will be the lowest WAC for any long-acting insulin glargine on the market.

The company announced the US launch of Semglee on 31 August, after the product, developed with partner Biocon, Ltd., was approved by the US Food and Drug Administration in June. (Also see "Not A Biosimilar: Mylan’s Insulin Glargine ‘Deemed’ A BLA With Long-Awaited US FDA Approval" - Pink Sheet, 11 June, 2020